{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:18:28Z","timestamp":1791119908762,"version":"4.1.0"},"reference-count":40,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2016,6,20]]},"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Many children with juvenile idiopathic arthritis (JIA) continue to have active disease into adulthood. Adults with JIA are a heterogeneous group, and the effects of tumour necrosis factor inhibitor (TNFi) therapies are not well described. This analysis aims to describe treatment outcomes among patients with JIA starting TNFi for the first time in adulthood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with arthritis onset &lt;16\u2005years starting their first TNFi therapy were identified from the British Society of Rheumatology Biologics Register. Disease activity outcomes (using 28-joint Disease Activity Score (DAS28) and Health Assessment Questionnaire (HAQ)) are presented at 1\u2005year after start of therapy according to disease pattern. Incidence rates (IR) of adverse events per 1000 person-years (pyrs) were calculated. Outcomes in patients with polyarticular JIA were compared with a cohort (weighted for age and gender) of patients with rheumatoid arthritis (RA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In 443 adults with JIA starting a first TNFi, disease activity over 1\u2005year improved across all measures. There were 58 first serious infections (IR 22.3\/1000 pyrs); 4 cardiovascular events (IR 1.4\/1000 pyrs); 11 uveitis events (IR 4.0\/1000 pyrs) and 16 malignancies (IR 3.9\/1000 pyrs). Compared with the weighted RA cohort, disease activity improvement was similar; malignancy rates were lower and uveitis rates much higher. While crude IR were similar, JIA patients had a lower risk of serious infection (HR 0.5 (95% CI 0.3 to 0.9)).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This is the largest study to describe disease activity and safety outcomes in adults with JIA receiving TNFi. Disease activity improved after 1\u2005year in all disease patterns, suggesting TNFi is an effective therapy in this population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2016-000273","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T23:10:14Z","timestamp":1475881814000},"page":"e000273","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis"],"prefix":"10.1136","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0377-1575","authenticated-orcid":false,"given":"Lianne","family":"Kearsley-Fleet","sequence":"first","affiliation":[{"name":"Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"McErlane","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology, Great North Children's Hospital, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E","family":"Foster","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology, Great North Children's Hospital, Newcastle upon Tyne, UK"},{"name":"Musculoskeletal Research Group, Institute Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lunt","sequence":"additional","affiliation":[{"name":"Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kath D","family":"Watson","sequence":"additional","affiliation":[{"name":"Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8625-1200","authenticated-orcid":false,"given":"Deborah P M","family":"Symmons","sequence":"additional","affiliation":[{"name":"Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK"},{"name":"NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimme L","family":"Hyrich","sequence":"additional","affiliation":[{"name":"Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK"},{"name":"NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,10,7]]},"reference":[{"key":"2025090313160904000_2.2.e000273.1","first-page":"1975","article-title":"Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register","volume":"23","author":"Symmons","year":"1996","journal-title":"J Rheumatol"},{"key":"2025090313160904000_2.2.e000273.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.34343"},{"key":"2025090313160904000_2.2.e000273.3","doi-asserted-by":"publisher","DOI":"10.2165\/11532610-000000000-00000"},{"key":"2025090313160904000_2.2.e000273.4","unstructured":"NHS England, specialise commissioning team. Clinical commissioning policy statement: biologic therapy is for the treatment of juvenile idiopathic arthritis. E03\/P\/d biologics for juvenile idiopathic arthritis in children and adults. 2015. https:\/\/www.england.nhs.uk\/commissioning\/wp-content\/uploads\/sites\/12\/2015\/10\/e03pd-bio-therapies-jia-oct15.pdf"},{"key":"2025090313160904000_2.2.e000273.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.10863"},{"key":"2025090313160904000_2.2.e000273.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.10444"},{"key":"2025090313160904000_2.2.e000273.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.12.1428"},{"key":"2025090313160904000_2.2.e000273.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.2.198"},{"key":"2025090313160904000_2.2.e000273.9","first-page":"579","article-title":"Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup","volume":"30","author":"Fantini","year":"2003","journal-title":"J Rheumatol"},{"key":"2025090313160904000_2.2.e000273.10","first-page":"1369","article-title":"Functioning and preferences for improvement of health among patients with juvenile idiopathic arthritis in early adulthood using the WHO ICF model","volume":"33","author":"Arkela-Kautiainen","year":"2006","journal-title":"J Rheumatol"},{"key":"2025090313160904000_2.2.e000273.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes019"},{"key":"2025090313160904000_2.2.e000273.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev195"},{"key":"2025090313160904000_2.2.e000273.13","unstructured":"EMA. Summary of product characteristics (Enbrel). European Medicines Agency, 2016 12\/01\/2016. Report No."},{"key":"2025090313160904000_2.2.e000273.14","doi-asserted-by":"crossref","unstructured":"Singh JA , Christensen R , Wells GA , et al . Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;(4):CD007848. doi:10.1002\/14651858.CD007848.pub2","DOI":"10.1002\/14651858.CD007848.pub2"},{"key":"2025090313160904000_2.2.e000273.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2013.04.005"},{"key":"2025090313160904000_2.2.e000273.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203341"},{"key":"2025090313160904000_2.2.e000273.17","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/acr.20188","article-title":"Predictors for remission in rheumatoid arthritis patients: a systematic review","volume":"62","author":"Katchamart","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313160904000_2.2.e000273.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev434"},{"key":"2025090313160904000_2.2.e000273.19","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2025090313160904000_2.2.e000273.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket248"},{"key":"2025090313160904000_2.2.e000273.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.042499"},{"key":"2025090313160904000_2.2.e000273.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2025090313160904000_2.2.e000273.23","doi-asserted-by":"publisher","DOI":"10.1080\/00207411.1994.11449283"},{"key":"2025090313160904000_2.2.e000273.24","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"2025090313160904000_2.2.e000273.25","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K"},{"key":"2025090313160904000_2.2.e000273.26","first-page":"561","article-title":"Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee","volume":"20","author":"Goldsmith","year":"1993","journal-title":"J Rheumatol"},{"key":"2025090313160904000_2.2.e000273.27","unstructured":"Office for National Statistics (ONS). Datasets and reference tables. http:\/\/www.ons.gov.uk\/ons\/datasets-and-tables\/index.html (accessed 20 Jan 2015)."},{"key":"2025090313160904000_2.2.e000273.28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel149"},{"key":"2025090313160904000_2.2.e000273.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.22531"},{"key":"2025090313160904000_2.2.e000273.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq242"},{"key":"2025090313160904000_2.2.e000273.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.34348"},{"key":"2025090313160904000_2.2.e000273.32","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/acr.21709","article-title":"Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents","volume":"64","author":"Nordstrom","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313160904000_2.2.e000273.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.27741"},{"key":"2025090313160904000_2.2.e000273.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.21675"},{"key":"2025090313160904000_2.2.e000273.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204851"},{"key":"2025090313160904000_2.2.e000273.36","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200103)44:3<523::AID-ANR99>3.0.CO;2-1"},{"key":"2025090313160904000_2.2.e000273.37","first-page":"958","article-title":"National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study","volume":"30","author":"Thomas","year":"2003","journal-title":"J Rheumatol"},{"key":"2025090313160904000_2.2.e000273.38","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.27218","article-title":"Mortality outcomes in pediatric rheumatology in the US","volume":"62","author":"Hashkes","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025090313160904000_2.2.e000273.39","first-page":"796","article-title":"Comorbidity profiles among adult patients with juvenile idiopathic arthritis: results of a biologic register","volume":"31","author":"Raab","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313160904000_2.2.e000273.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201969"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2016-000273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:16:22Z","timestamp":1756930582000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2016-000273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,10,7]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1136\/rmdopen-2016-000273"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2016-000273","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}